Clinical trial
A Study of Dulanermin in Combination With Rituximab in Subjects With Follicular…
NCT00400764 · Genentech, Inc., Industry · Terminated
Key facts
| NCT number | NCT00400764 |
|---|---|
| Title | A Study of Dulanermin in Combination With Rituximab in Subjects With Follicular and Other Low Grade, CD20+, Non-Hodgkin's Lymphomas |
| Official title | A Phase Ib/II, Open-Label, Multicenter Study of the Safety, Pharmacokinetics, and Efficacy of Dulanermin Administered Intravenously in Combination With Rituximab to Subjects With Follicular and Other Low-Grade, CD20+, B-Cell Non-Hodgkin's Lymphomas That Have Progressed Following Previous Rituximab… |
| Lead sponsor | Genentech, Inc., Industry |
| Collaborators | Amgen Industry |
| Status | Terminated |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Non-Hodgkin's Lymphoma |
| Intervention type | Drug |
| Interventions | Dulanermin, Rituximab |
| Enrollment | 72 |
| Start date | Jun 1, 2006 |
| Primary completion | May 1, 2010 |
| First posted | Nov 17, 2006 |
| Last update posted | Nov 23, 2011 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: